Rabbit Recombinant Monoclonal CFHR1 antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
WB | ICC/IF | IHC-P | |
---|---|---|---|
Human | Tested | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/10000 | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500 | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH. Can associate with lipoproteins and may play a role in lipid metabolism.
CFH
CFHL, CFHL1, CFHL1P, CFHR1P, FHR1, HFL1, HFL2, CFHR1, Complement factor H-related protein 1, FHR-1, H factor-like protein 1, H36, FHL-1, H-factor-like 1
Rabbit Recombinant Monoclonal CFHR1 antibody. Suitable for WB, ICC/IF, IHC-P and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Complement Factor H (CFH) and Complement Factor H-Like 1 (CFHL1) are important proteins involved in the regulation of the complement system. CFH is also known as CFH band and has a molecular mass of approximately 150 kDa. These proteins are mainly expressed in the liver and are present in plasma. CFHL1 is a truncated version of CFH and shares structural similarities with it. Both proteins have an important role in maintaining balance in the immune system.
CFH and CFHL1 control the activity of the alternative complement pathway by inhibiting the formation of the C3 convertase and promoting the disassembly of the convertase complexes. This process prevents overactivation of the complement system which can otherwise damage host tissues. CFH functions as a cofactor for factor I aiding in the degradation of C3b. Both proteins are not part of a larger complex but interact with other components in the pathway to regulate complement activation.
Both CFH and CFHL1 play essential roles in the alternative complement pathway and the regulation of complement cascades. They interact closely with proteins like C3b and factor I to modulate the immune response. This regulation is important for preventing unintentional cellular damage and ensuring proper immune function. CFH particularly ensures that this pathway does not escalate into an inflammatory reaction in healthy tissues.
Defects or deficiencies in CFH or CFHL1 relate to conditions like age-related macular degeneration (AMD) and atypical hemolytic uremic syndrome (aHUS). These diseases link to uncontrolled complement activation and tissue damage. In AMD CFH's interaction with proteins like C3 is important for preventing retinal damage. For aHUS CFH mutations disrupt normal function leading to excessive complement activity and renal injury.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking/Dilution buffer: 5% NFDM/TBST.
Based on the sequence analysis, ab200656 has 100% homology with CFH protein.
The observed MW is consistent with what has been described in the literature PMID: 19745068.
All lanes: Western blot - Anti-CFH + CFHL1 antibody [EPR17159] (ab200656) at 1/10000 dilution
Lane 1: Human serum at 10 µg
Lane 2: Human plasma at 10 µg
Lane 3: Human fetal liver tissue lysate at 10 µg
All lanes: Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 38 kDa
Observed band size: 180 kDa, 38 kDa, 44 kDa
Exposure time: 3min
Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling CFH + CFHL1 with ab200656 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) secondary antibody at 1/500 dilution.
Cytoplasm staining on Human liver tissue is observed.
Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin-embedded Human placenta tissue labeling CFH + CFHL1 with ab200656 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) secondary antibody at 1/500 dilution.
Plasma staining on Human placenta tissue is observed.
Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin-embedded Human lung carcinoma tissue labeling CFH + CFHL1 with ab200656 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) secondary antibody at 1/500 dilution.
Human Lung carcinoma tissue was used as a negative control for CFH + CFHL1.
Counter stained with Hematoxylin.
Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/500 dilution.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Immunofluorescent analysis of 100% methanol-fixed, 0.1% Triton X-100 permeabilized HepG2 (Human liver hepatocellular carcinoma) cells labeling CFH + CFHL1 with ab200656 at 1/100 dilution, followed by Goat anti-rabbit IgG (Alexa Fluor® 488) (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) secondary antibody at 1/500 dilution (green).
Cytoplasm staining on HepG2 cell line is observed.
The nuclear counter stain is DAPI (blue).
Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution and Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution (red).
The negative controls are as follows:
-ve control 1: ab200656 at 1/100 dilution followed by Goat Anti-Mouse IgG H&L (Alexa Fluor® 594) preadsorbed ab150120 (AlexaFluor®594 Goat anti-Mouse secondary) at 1/500 dilution.
-ve control 2: Anti-alpha Tubulin antibody [DM1A] - Loading Control ab7291 (anti-Tubulin mouse mAb) at 1/1000 dilution followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077 (Alexa Fluor®488 Goat Anti-Rabbit IgG H&L) at 1/500 dilution.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com